IntelePeer Achieves HITRUST r2 Certification Demonstrating the Highest Level of Information Protection Assurance
'Earning the HITRUST r2 Certification is a testament to the rigorous standards we uphold at IntelePeer to safeguard sensitive healthcare data,' said Frank Fawzi, CEO of IntelePeer. 'This achievement underscores our commitment to helping healthcare organizations deliver secure, seamless, and efficient patient experiences, while trusting us as a reliable partner in their digital transformation journey.'
HITRUST r2 Certification demonstrates that the organization's AI Hub and Smart solutions have met demanding regulatory compliance and industry-defined requirements and is appropriately managing risk. This achievement places IntelePeer in an elite group of organizations worldwide that have earned this certification. By including federal and state regulations, standards, and frameworks and incorporating a risk-based approach, the HITRUST Assurance Program helps organizations address security and data protection challenges through a comprehensive and flexible framework of prescriptive and scalable security controls.
' HITRUST certification is globally recognized as validation that information security and privacy controls are effective and compliant with various regulations. HITRUST certification isconsidered the gold standard because of the comprehensiveness and applicability of the control requirements, depth of the assurance process, and level of oversight that ensures accuracy,' said Jeremy Huval, Chief Innovation Officer at HITRUST.
IntelePeer's AI Hub, a unified platform that integrates communication management, enables healthcare providers to keep up with evolving patient expectations with its analytics and insights, process automation, and secure AI. The Hub provides an all-in-one hyper-automation solution designed to offer exceptional patient experiences without reliance on live agents leading to lower costs, enhanced efficiency, and improved customer experiences. SmartAgent automates inbound interactions, helping providers to quickly and easily streamline agent responsibilities and empower self-service for a much faster ROI. It allows practices to manage spikes in call capacity, reduce costs, and avoid compliance issues. SmartOffice offers unparalleled automation and enhanced interaction resolution for multi-location practices. It allows for routine patient interactions to be addressed without the need for direct human interaction, giving staff time back to focus on more complex patient needs.
About IntelePeer
IntelePeer streamlines customer interactions, enabling businesses and contact centers to lower costs, improve customer experience, and accelerate return on investment. Harnessing the power of agentic AI, IntelePeer's Conversational AI Platform delivers speed, observability, visibility, and flexibility — all built on top of a global, secure communications network. Producing human-like interactions, the platform automates voice and digital customer service capabilities and provides industry-leading time-to-value with solutions that work seamlessly with existing enterprise software and infrastructure, and easy-to-use tools that can be utilized by anyone.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
19 minutes ago
- Business Wire
Wikifarmer Launches UK Operations to Transform Olive Oil Sourcing for British Businesses
LONDON--(BUSINESS WIRE)--Wikifarmer, the Athens and Seville-based online agricultural marketplace, is launching UK operations to connect British businesses directly with Mediterranean olive oil producers. With Spanish olive oil prices down 53% year-over-year to €3.55/kg¹, this expansion targets Britain's £320 million olive oil market², projected to reach $1.55 billion by 2030⁶. "Our platform offers free access to quality European producers, with no hidden charges" Share Direct Access. Lower Costs. Greater Transparency. Wikifarmer's platform connects businesses directly with verified Mediterranean producers, eliminating intermediaries to provide transparent pricing, reliable logistics, and flexible credit terms with no subscription fees. The free-to-use model has connected over 7,000 buyers with 15,000 suppliers, facilitating millions in direct trade transactions. "The UK represents a massive opportunity to revolutionize how British businesses source Mediterranean olive oil," says Wikifarmer Co-Founder and CEO, Ilias Sousis. "We offer buyers direct access to quality European producers with the reliability and support they demand." Meeting UK Market Needs British businesses faced olive oil import price increases of 44% in 2024 while dealing with supply chain uncertainties. "Our platform offers free access to quality European producers, with no hidden charges," says Sam Frearson, UK Sales Manager. The UK's £128 billion food and agriculture sector¹¹ relies on traditional supply chains with multiple intermediaries, driving up costs and reducing transparency. Spain supplies 62% of UK olive oil imports, Italy 26%⁴, but most trade passes through costly middlemen. UK olive oil import values rose 31.7% to £333.2 million in 2023⁸, with olive oil comprising 87.1% of Britain's olive market⁷. Recent recovery in global production and a 13.9% drop in EU prices signal market stabilization¹⁰, making now ideal for direct sourcing. Expansion Plans The UK team will focus on onboarding buyers in wholesale, hospitality, retail, and food processing. This expansion advances Wikifarmer's vision to create a digital marketplace connecting farmers directly with buyers, eliminating intermediaries for fair, transparent trade. The company plans further European expansion throughout 2025. About Wikifarmer Wikifarmer ( combines the world's largest agricultural knowledge library with an online B2B marketplace. With over 20,000 direct transactions, Wikifarmer helps businesses reduce costs and supports farmers' profitability.
Business Wire
an hour ago
- Business Wire
JR-PLUS & Cinnamoroll Collaborative Campaign Starts!
NAGOYA, Japan & TOKYO--(BUSINESS WIRE)--During the period from Tuesday, August 19, to Monday, September 8, 2025, JR Central Retailing Plus Co., Ltd. stores will hold a Cinnamoroll Collaborative Campaign in conjunction with Cinnamoroll, the popular character from Sanrio Company, Ltd. In this campaign, stores will sell station lunchboxes (ekiben) and original goods only available through this collaboration, created with the concept of 'Cinnamoroll and his friends are helping out at station shops!' Two types of original 'KAWAII' illustrations only available during this campaign Uniform version for JR Central, which runs the Tokaido Shinkansen Uniform version as a chef, which is Cinnamoroll's 'dream' Sale of original collaborative goods Original goods with designs created specifically for this fair will be on sale. Ball chain mascot JR Central uniform ver.: 2,618 yen Ball chain mascot cafe uniform ver.: 2,618 yen Face coin purse: 1,540 yen Tote bag: 2,530 yen Drawstring bag 2P: 1,408 yen Three-pocket clear pouch: 2,178 yen Onigiri case (with carabiner): 2,178 yen Acrylic key chains (6 types): 770 yen each (4,620 yen for a box) Button badges (10 types): 550 yen each (5,500 yen for a box) Sale of original ekiben created in collaboration with Cinnamoroll Cinnamoroll Ekiben: 1,580 yen Other limited-offer collaborative package onigiri, sandwiches, and sweets will also be offered. Cinnamoroll Collaborative Campaign overview - Campaign dates: Tuesday, August 19, 2025 to Monday, September 8, 2025 - Campaign locations: Plusta, Bellmart, Grand Kiosk, Gift Kiosk, Precious Deli & Gift, etc. at Tokyo Station, Shinagawa Station, Shizuoka Station, Nagoya Station, Kyoto Station, Shin-Osaka Station, and others. See details here © 2025 Sanrio Co., Ltd. Approval No. L661918 *All prices include consumption tax. *All images are for illustrative purposes.
Business Wire
an hour ago
- Business Wire
Sensorion Completes Patient Enrollment of the Second Cohort in Audiogene Phase 1/2 Gene Therapy Clinical Trial
MONTPELLIER, France--(BUSINESS WIRE)--Regulatory News: Sensorion (FR0012596468 – ALSEN), a pioneering clinical-stage biotechnology company specializing in the development of novel therapies to restore, treat and prevent hearing loss disorders, today announced the completion of patient enrollment in the second cohort of its Phase 1/2 Audiogene clinical trial evaluating SENS-501, the Company's gene therapy candidate being developed to treat a specific form of congenital deafness linked to mutations in the OTOF (otoferlin) gene. Recruitment of the second cohort, composed of three patients aged between 6 and 31 months, was recently completed with the injection of the third patient. Patients in this second cohort were administered, unilaterally, a dose of d4.5 E 11 vg/vector/ear of SENS-501 which was higher than the dose in the 1 st cohort (1.5 E 11 vg/vector/ear). For all patients treated in the first and second cohorts, the surgical procedure was well tolerated: the intra-cochlear administration of the gene therapy product was uneventful. No serious adverse events and no serious side effects were reported. Early signs of hearing improvement have been observed in Patient 3, aged 11 months at the time of injection, three months after receiving the low dose. Nawal Ouzren, Chief Executive Officer of Sensorion, commented: "The completion of patient enrollment in the second cohort in Audiogene is an important milestone as it enables us to attest to the safety of the surgical approach, as no serious adverse events have been observed in all six patients injected, and of the good tolerability of SENS-501 to date. I look forward to advancing this innovative and unique program to its next steps, notably with the planned Data Monitoring Committee meeting, and to providing an update as soon as the data have sufficiently matured. On behalf of my colleagues, I would like to extend gratitude to the patients' families for their trust, as well as all the healthcare professionals involved in this clinical trial.' Professor Natalie Loundon, M.D., Director of the Center for Research in Pediatric Audiology, Pediatric Otolaryngologist and Head and Neck Surgeon, Necker Enfants Malades, AP-HP, in Paris, France, Principal Investigator of the Audiogene clinical study, added: 'I am thrilled we have successfully completed the patient enrollment of the second Cohort in Audiogene's Phase 1/2 gene therapy trial. The good tolerability of patients to SENS-501 so far and the preliminary positive data from the first cohort are very encouraging first steps for the continuation of this trial that has the potential to address a global significant unmet medical need. Once again, I would like to thank the patients' families for their trust.' Audiogene ( ID: NCT06370351) is the first gene therapy clinical trial addressing a unique homogeneous population of infants and toddlers (aged 6 to 31 months and naive of cochlear implants at the time of the injection, as per study protocol). Audiogene's clinical trial design has been intended to assess SENS-501 gene therapy product's safety and tolerability as well as its capacity not only to restore hearing but also to allow the infants and toddlers to acquire and develop normal speech. Moreover, Audiogene aims to evaluate the usability, the clinical and the technical performances of the injection system in development. About SENS-501 SENS-501 (OTOF-GT) is an innovative gene therapy program developed to treat a specific form of congenital deafness linked to mutations in the OTOF (otoferlin) gene. This gene plays a key role in the transmission of auditory signals between the hair cells of the inner ear and the auditory nerve. When this gene is defective, affected individuals are born with severe to profound hearing loss. The aim of SENS-501 (OTOF-GT) is to restore hearing by introducing a functional copy of the OTOF gene directly into hair cells via viral vector technology (AAV). This therapy aims to restore the normal process of converting sound into electrical signals, enabling patients to regain their hearing ability. Currently in the clinical research phase, this gene therapy program represents significant hope for families affected by this rare form of genetic deafness. SENS-501 (OTOF-GT) embodies a commitment to scientific innovation in the field of hearing, with the potential to dramatically improve the quality of life of patients suffering from genetic deafness. This gene therapy for patients suffering from otoferlin deficiency has been developed in the framework of RHU AUDINNOVE, a consortium composed of Sensorion with the Necker Enfants Malades Hospital, the Institut Pasteur, and the Fondation pour l'Audition. The project is partially financed by the French National Research Agency, through the 'investing for the future' program (ref: ANR-18-RHUS-0007). The OTOF gene targeted by the Audiogene trial was discovered in 1999 at the Institut Pasteur, by Prof. Christine Petit's team (Institut reConnect, Institut de l'Audition, Pasteur Institute), who also unraveled the pathophysiology of the corresponding deafness (DFNB9). About the Audiogene Trial Audiogene aims to evaluate the safety, tolerability and efficacy of intra-cochlear injection of SENS-501 for the treatment of OTOF gene-mediated hearing loss in infants and toddlers aged 6 to 31 months at the time of gene therapy treatment. By targeting the first years of life, when brain plasticity is optimal, the chances of these young children with pre-linguistic hearing loss acquiring normal speech and language are maximized. The study comprises two cohorts of two doses followed by an expansion cohort at the selected dose. While safety will be the primary endpoint of the first part of the dose escalation study, auditory brainstem response (ABR) will be the primary efficacy endpoint of the second part of the expansion. Audiogene will also evaluate the clinical safety, performance and ease-of-use of the delivery system developed by Sensorion. About Sensorion Sensorion is a pioneering clinical-stage biotech company, which specializes in the development of novel therapies to restore, treat, and prevent hearing loss disorders, a significant global unmet medical need. Sensorion has built a unique R&D technology platform to expand its understanding of the pathophysiology and etiology of inner ear related diseases, enabling it to select the best targets and mechanisms of action for drug candidates. It has two gene therapy programs aimed at correcting hereditary monogenic forms of deafness, developed in the framework of its broad strategic collaboration focused on the genetics of hearing with the Institut Pasteur. SENS-501 (OTOF-GT) currently being developed in a Phase 1/2 clinical trial, targets deafness caused by mutations of the gene encoding for otoferlin and GJB2-GT targets hearing loss related to mutations in GJB2 gene to potentially address important hearing loss segments in adults and children. The Company is also working on the identification of biomarkers to improve diagnosis of these underserved illnesses. Sensorion's portfolio also comprises programs of a clinical-stage small molecule, SENS-401 (Arazasetron), for the treatment and prevention of hearing loss disorders. Sensorion's small molecule progresses in a Phase 2 proof of concept clinical study of SENS-401 in Cisplatin-Induced Ototoxicity (CIO) for the preservation of residual hearing. Sensorion, with partner Cochlear Limited, completed in 2024 a Phase 2a study of SENS-401 for the residual hearing preservation in patients scheduled for cochlear implantation. A Phase 2 study of SENS-401 was also completed in Sudden Sensorineural Hearing Loss (SSNHL) in January 2022. Disclaimer This press release contains certain forward-looking statements concerning Sensorion and its business. Such forward looking statements are based on assumptions that Sensorion considers to be reasonable. However, there can be no assurance that such forward-looking statements will be verified, which statements are subject to numerous risks, including the risks set forth in the 2024 full year report published on March 14, 2025, and available on our website and to the development of economic conditions, financial markets and the markets in which Sensorion operates. The forward-looking statements contained in this press release are also subject to risks not yet known to Sensorion or not currently considered material by Sensorion. The occurrence of all or part of such risks could cause actual results, financial conditions, performance or achievements of Sensorion to be materially different from such forward-looking statements. This press release and the information that it contains do not constitute an offer to sell or subscribe for, or a solicitation of an offer to purchase or subscribe for, Sensorion shares in any country. The communication of this press release in certain countries may constitute a violation of local laws and regulations. Any recipient of this press release must inform oneself of any such local restrictions and comply therewith.
